<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Liver Cancer PDX Models

Liver cancer is the second leading cause of cancer-related deaths worldwide. Due to this, there is a need for more predictive and relevant preclinical models to provide better insights into clinical outcomes when evaluating new cancer therapies. Patient-derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. Crown Bioscience’s collection consists of a large number of liver cancer PDX models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
LI0050 Liver Cancer HCC Hepatocellular carcinoma from middle lobe of liver, grade IV, G4-S4, cancer embolus were observed in part of vessels, nodular cirrhosis presented surrounding liver tissues, fatty degeneration (about 10~15%) were observed. CLICK TO VIEW
LI0334 Liver Cancer HCC Hepatic nodular cirrhosis with hepatocelluar carcinoma; chronic cholecystitis. CLICK TO VIEW
LI0348 Liver Cancer HCC Postnecrotic cirrhosis with combined cell type carcianoma; Postnecrotic cirrhosis with mixed carcinoma of liver. CLICK TO VIEW
LI0574 Liver Cancer HCC Hepatocellular carcinoma CLICK TO VIEW
LI0612 Liver Cancer HCC Postnecrotic cirrhosis with hepatocellular carcinoma. Chronic cholecystitis. CLICK TO VIEW
LI0752 Liver Cancer HCC Right lobes massive type hepatocelluar carcinoma; Hepatocellular carcinoma from liver right lobe, accompanied with necrosis, tumor mass: 14cm x 12cm x 10cm. Chronic cholecystitis, cholelithiasis. IHC result: CK(++), CK7(-), CK18(++), CK19(++), CEA(-), AFP(-). CLICK TO VIEW
LI0801 Liver Cancer HCC Early hepatocirrhosis with hepatocarcinoma. Chronic cholecystitis. Cholelithiasis. CLICK TO VIEW
LI0941 Liver Cancer SCC NA CLICK TO VIEW
LI1004 Liver Cancer HCC Hepatocellular carcinoma, grade II, with nodular cirrhosis. IHC results: AFP(+), HEPA(partial +), PDEC(100%++), P48(-), CK7(-), CD34(abundant blood sinus ), CK19(-), PERK(-). CLICK TO VIEW
LI1005 Liver Cancer HCC Hepatocellular carcinoma. Chronic cholecystitis. IHC results: AFP(+), HEPA(+), PDEC(++), P48(-), CK7(-), CD34 (massive vessel +), CK19(-), PERK(-). CLICK TO VIEW
LI1025 Liver Cancer HCC Hepatocellular carcinoma, with necrosis, nodular cirrhosis presented in periphery liver with a small amount of hepatocyte fatty degeneration. IHC results: AFP(+), HEPA (+), PDEC(part +), CK7(bile duct +), CD34(vessel +), CK19(bile duct +), PERK(-). CLICK TO VIEW
LI1035 Liver Cancer HCC Hepatocellular carcinoma, tumor embolus in individual vessel, fibrous tissues hyperplasia with part of fibrous septum formation. IHC results: AFP(+/-), HEPA(+), PDEC(+), PERK(-), CD34(vessel +), CK7(+), CK19(+). CLICK TO VIEW
LI1037 Liver Cancer HCC Hepatocellular carcinoma, haemorrhage, necrosis, fibrous tissues mild hyperplasia, chronic cholecystitis, IHC results: AFP (-), HEPA (+), PDEC (-), CD34 (vessel +), CK7 (bile duct +), CK19 (bile duct +), PERK (-). CLICK TO VIEW
LI1054 Liver Cancer HCC Epithelioid malignant tumor, consider hepatocellular carcinoma, grade II, with massive necrosis, nodular cirrhosis, fibrous tissues hyperplasia with part of fibrous septum formation, IHC results: AFP(-), HEPA (-), PDEC( little focus +), P48(-), CD34 (vessel +), CK19 (+), PERK (-), PAKT (-), PMEK1/2(-), CK7(part +). CLICK TO VIEW
LI1055 Liver Cancer HCC Epithelioid malignant tumor, consider mixed liver cancer, hepatocellular carcinoma and adenocarcinoma of bile duct, lympha cells invade portal area with fibrous tissues hyperplasia, IHC results: AFP(-), HEPA(-), PDEC(part +), P48(-), CD34 (vessel +), CK19 (+), PERK(-), PAKT(-), PMEK1/2(-), CK7(+), CK20(part +), CEA(part +). CLICK TO VIEW
LI1057 Liver Cancer HCC Hepatocellular carcinoma with massive necrosis, grade II-III. IHC results: AFP(-), HEPA(-), PDEC(-), P48(-), CD34(blood vessel +), CK19(biliary ducts +), CK7(biliary ducts +), PERK(-), PAKT(-), PMEK1/2(-). CLICK TO VIEW
LI1058 Liver Cancer HCC Hepatocellular carcinoma with massive necrosis, grade II-III, lympha cells infiltrated portal area with fibrous tissues hyperplasia. IHC results: AFP(-), HEPA(-), PDEC(-), P48(-), CD34(blood vessle +), CK19(-), PERK(-), PAKT(-), CK (part +), PMEK1/2(-). CLICK TO VIEW
LI1068 Liver Cancer HCC Hepatocellular carcinoma, tumor cells scattered within liver, tumor embolus in vessel, nodular cirrhosis presented in periphery liver. IHC results: AFP(++), HEPA(+), PDEC(-), P48(-),CD34(+), CK19(-), PERK(-), PEKT(-), PEMK1/2(-). CLICK TO VIEW
LI1069 Liver Cancer HCC Hepatocellular carcinoma, with part of necrosis, tumor embolus in individual vessel, nodular cirrhosis presented in periphery liver. Chronic cholecystitis. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34(+), CK19(+), PERK(-), PEKT(-), PEMK1/2(-). CLICK TO VIEW
LI1074 Liver Cancer HCC Neuroendocrine carcinoma in liver. PDX pathology QC as HCC. CLICK TO VIEW
LI1078 Liver Cancer HCC Hepatocellular carcinoma, with necrosis, tumor embolus in vessel, nodular cirrhosis presented in periphery liver. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34(+), CK19(+), PERK(-), PAKT(-), PEMK1/2(-), CK7(-). CLICK TO VIEW
LI1081 Liver Cancer HCC Hepatocellular carcinoma, diffuse in liver, cancer embolus in vessel. IHC results: AFP(<5%+), HEPA(100%+++), CD34(massive vessel), CK19(-), PDEC(10%+), p53(20%++-+++), EGFR(-), HER2(<5%+), Ki-67(about 15%++). CLICK TO VIEW
LI1088 Liver Cancer HCC Hepatocellular carcinoma, with necrosis, cancer embolus in vessel, G2S2. IHC results: AFP(+), HEPA(+), PDEC(-), P48(-), CD34 (vessel +), CK7(bile duct +), CK19(bile duct +), PERK(-), hTERT(-), LYVE-1(-). CLICK TO VIEW
LI1097 Liver Cancer HCC Hepatocellular carcinoma of middle lobe, grade II-III, peripheral hepatic tissue G2S4. Chronic cholecystitis. Cholecyslithiasis. CLICK TO VIEW
LI1098 Liver Cancer HCC Hepatocellular carcinoma of right lobe, grade II, peripheral hepatic tissue G1S1. CLICK TO VIEW
LI11482 Liver Cancer NA NA CLICK TO VIEW
LI1549 Liver Cancer NA Nodular cirrhosis with hepatocellular carcinoma. CLICK TO VIEW
LI1646 Liver Cancer HCC Nodular cirrhosis with hepatocellular carcinoma, hemorrhagic necrosis. CLICK TO VIEW
LI2169 Liver Cancer HCC Hepatocellular carcinoma, moderately to poorly differentiated. Tumor size: 4X 3.5X 3cm. IHC results: AFP(part cells, +), CD34(+), CK18(+), CK19(-), CK7(several cells +), CK8(+), EMA(several cells +), hepatocyte(+). CLICK TO VIEW
LI2231 Liver Cancer ADC N/A CLICK TO VIEW
LI2800 Liver Cancer Adenocarcinoma NA CLICK TO VIEW
LI2842 Liver Cancer Adenocarcinoma NA CLICK TO VIEW
LI2893 Liver Cancer NA NA CLICK TO VIEW
LI3205 Liver Cancer HCC Hepatocellular carcinoma, Edmondson III CLICK TO VIEW
LI3243 Liver Cancer HCC NA CLICK TO VIEW
LI5129 Liver Cancer HCC liver carcinoma hepatocellular carcinoma. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
LI5130 Liver Cancer HCC liver carcinoma sarcomatoid hepatocellular carcinoma. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
LI5131 Liver Cancer ADC N/A CLICK TO VIEW
LI5132 Liver Cancer HCC, fibrolamellar type hepatocellular carcinoma, metastatic hepatocellular carcinoma, fibrolamellar type. Pathol comment: c/w diagnosis. approximately 25% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
LI6206 Liver Cancer NEC Liver: poorly differentiated neuroendocrine carcinoma. Please exclude metastatic carcinoma based on clinical information and medical history. CLICK TO VIEW
LI6278 Liver Cancer HCC N/A CLICK TO VIEW
LI6280 Liver Cancer NEC? HCC? Right lobe of liver: hepatocellular carcinoma, spindle cell type, grade III, with sarcomatoid type and mixed type cirrhosis. CLICK TO VIEW
LI6281 Liver Cancer HCC N/A CLICK TO VIEW
LI6291 Liver Cancer NA NA CLICK TO VIEW
LI6292 Liver Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
LI6293 Liver Cancer HCC Hepatocellular carcinoma, grade III CLICK TO VIEW
LI6294 Liver Cancer HCC Hepatocellular carcinoma, grade III CLICK TO VIEW
LI6295 Liver Cancer HCC N/A CLICK TO VIEW
LI6297 Liver Cancer HCC Hepatocellular carcinoma, grade III CLICK TO VIEW
LI6301 Liver Cancer HCC NA CLICK TO VIEW
LI6306 Liver Cancer HCC Intrahepatic cholangiocarcinoma, moderately differentiated CLICK TO VIEW
LI6601 Liver Cancer HCC Left lobe of liver: cholangiocarcinoma, grade II-III, periphery hepatic tissues, G1S3. Pathology QC on PDX as HCC. CLICK TO VIEW
LI6610 Liver Cancer HCC Left lobe of liver: hepatocellular carcinoma, grade II-III, peripheral hepatic tissues show nodular cirrhosis G2S4. IHC result: AFP(-), Hepa(+), CD34(abundant blood sinus), CK19(-), CK7(partial cells +), KI67(15%+), Thromblin(partial cells +), GP73(100%+++), CD8(about 5/HPF), CD151(-), OPN(90%+), IL-2(-). CLICK TO VIEW
LI6611 Liver Cancer HCC Cholangiocarcinoma. Pathology QC: HCC with massive necrosis (P5, P6) CLICK TO VIEW
LI6612 Liver Cancer HCC Right lobe of liver: hepacellular carcinoma, grade II, with hemorrhagic necrosis. Peripheral hepatic tissues showed nodular cirrhosis G1-2S4e. IHC result: AFP(++), Hepa(+), CK7(-), CK19(-), CD34(abundant blood sinus), GP73(+), Thromblin(+), IL-2(focal +), KI67(30%+), CD8(about 10/HPF), OPN(-), CD56(-), CD117(-). CLICK TO VIEW
LI6615 Liver Cancer HCC Righr lobe of liver: hepatocellular carcinoma, grade II-III, with haemorrhagia necrosis. Peripheral hepatic tissues showed nodular cirrhosis G1-2S4. CLICK TO VIEW
LI6616 Liver Cancer HCC Left lobe of liver: hepatocellular carcinoma, grade II-III, with massive necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2S3. CLICK TO VIEW
LI6617 Liver Cancer HCC Mixed carcinoma of liver (HCC and Cholangiocarcinoma) CLICK TO VIEW
LI6619 Liver Cancer HCC Right lobe of liver: hepacellular carcinoma, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis G2S2. IHC result: AFP(++), Hepa(++), CK7(few +), CK19(70%+), CD34(abundant blood sinus), GPC3(100%+), KI67(80%+), CD8(about 20/HPF), CD151(-), GS(100%++), HSP70(80%+), CD56(-), CD117(-). CLICK TO VIEW
LI6622 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III. IHC results: AFP(-), Hepa(100%+++), CD34(abundant blood vessel), CK19(-), CK7(-), KI67(50%+), Thromblin(90%++), GP73(100%+++), CD8(30/HPF), IL-2(-), CD151(-), OPN(-). CLICK TO VIEW
LI6628 Liver Cancer Mixed carcinoma of liver (HCC and Cholangiocarcinoma) Right lobe of liver: poorly differentiated adenocarcinoma, stromal invasion and massive necrosis could be seen, accorded with mixed carcinoma of hepatocellular carcinoma and cholangiocarcinoma based on morphology, clinical information and IHC results. Peripheral hepatic tissues showed nodular cirrhosis G2S4 (hepatocyte fatty degeneration <5%). CLICK TO VIEW
LI6643 Liver Cancer HCC Liver: hepatocellular carcinoma, grade III, with necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2S4F0. IHC results: AFP(-), Hepa(-), CK7(5%+), CK19(5%+), CD34(abundant blood vessel), KI67(40%+), GS(80%++), GPC-3(80%++), HSP70(60%+~++). CLICK TO VIEW
LI6646 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis. IHC results: AFP(-), Hepa(-), CD34(blood vessel +), CK19(90%+), CK7(5%+), KI67(40%+), Thromblin(-), GP73(100%+++), CD8(20/HPF), IL-2(10%+), CD151(-), OPN(70%+), CD68(histocyte +). CLICK TO VIEW
LI6649 Liver Cancer HCC NA CLICK TO VIEW
LI6650 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma with necrosis, grade II-III. Peripheral hepatic tissues showed nodular cirrhosis G2S4. CLICK TO VIEW
LI6652 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III. CLICK TO VIEW
LI6653 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II, with necrosis. Peripheral hepatic tissues showed nodular cirrhosis G2-3S4. IHC results: AFP(focal +), Hepa(part +), CK7(-), CK19(+++), CD34(abundant blood sinus) KI67(70%+), HSP70(++), GPC3(part +), SYN(-), CHG(-), CD56(-). CLICK TO VIEW
LI6654 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis with fatty degeneration (35%). CLICK TO VIEW
LI6656 Liver Cancer HCC Left lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis G2S4. CLICK TO VIEW
LI6659 Liver Cancer HCC NA CLICK TO VIEW
LI6660 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II. Peripheral hepatic tissues showed nodular cirrhosis. IHC results: AFP(-), Hepa(100%+++), CD34(massive blood vessel), CK19(-), CK7(10%+), Ki67(20%+), Thromblin(30%+), GP73(100%+++), CD8(10/HPF), IL-2(-), CD151(-), OPN(90%+), CD68(histocyte +). CLICK TO VIEW
LI6662 Liver Cancer HCC Special hepatic segments: hepatocellular carcinoma, grade II, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G2S4. IHC result: AFP(-), Hepa(80%++), CK7(-), CK19(-), CD34(abundant blood sinus), GPC3(80%+), KI67(10%+), GS(100%+~++), HSP70(70%++). CLICK TO VIEW
LI6663 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III, with massive necrosis. IHC results: AFP(50%+), Hepa(50% weak +), CK7(5%+), CK19(100%++), CD34(abundant blood sinus), GPC3(40%+), KI67(40%+), CD8(5 /HPF), OPN(10%+), CD151(-), ARG-1(30%+), CD56(small +), CD117(-). CLICK TO VIEW
LI6664 Liver Cancer HCC Right lobe of liver: mixed hepatocellular carcinoma, moderately differentiated. Cancer embolus presents in many vessels, periphery hepatic tissues: G1S2. IHC results: c-Met(++), CD151(cell nucleus +), CD34(abundant blood sinus), CK19(++), CD56(-), KI67(80%+), EPCAM(membrane +), B-cat(membrane +), OPN(-). CLICK TO VIEW
LI6665 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II, with massive necrosis. Peripheral hepatic tissues showed hodular cirrhosis G2S4. IHC results: AFP(-), Hepa(+), CK7(-), CK19(-), CD34(abundant blood sinus), KI67(40%+), CD8(50/HPF), OPN(90%+), EPCAM(-), GP73(100%++), ARG-1(60%+), CD56(-), CD117(-). CLICK TO VIEW
LI6668 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III. Peripheral hepatic tissues showed hodular cirrhosis G1S4. CLICK TO VIEW
LI6669 Liver Cancer HCC Transcoelomic metastasis foci of abdominal cavity: malignant epithelial tumor, accorded with hepatocellular carcinoma based on medical history and IHC results, grade II-III, with necrosis. IHC results: AFP(focal +), Hepa(focal+), CK7(-), CK19(disperse +),CD34(blood vessel +), KI67(70%+), GS(++), HSP70(+++), GPC3(focal +), CD56(-), CD117(-). CLICK TO VIEW
LI6671 Liver Cancer ADC? HCC? Middle lobe of liver and gall bladder: poorly differentiated adenocarcinoma. Consider gall bladder carcinoma on the basis of IHC results. One of four lymph node involved by metastatic carcinoma (1/4). CLICK TO VIEW
LI6674 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma, grade II-III, with necrosis. Peripheral hepatic tissues showed hodular cirrhosis G2-3S4. All lypho nodes are benign (0/7). IHC results: AFP(20%+), Hepa(40%+), CK7(-), CK19(2%+), CD34(abundant blood sinus), GP73(70%+), Thromblin(10%+), KI67(70%+), CD8(20/HPF), OPN(40%+), CD56(scattered +),CD117(scattered +) CLICK TO VIEW
LI6675 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma with massive necrosis, grade II-III. Peripheral hepatic tissues showed hodular cirrhosis G2S3. CLICK TO VIEW
LI6676 Liver Cancer HCC Special hepatic segments: hepatocellular carcinoma, grade II-III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G3S4. CLICK TO VIEW
LI6677 Liver Cancer HCC Right lobe of liver: hepatocellular carcinoma with necrosis, grade II. Peripheral hepatic tissues showed hodular cirrhosis G2S4. CLICK TO VIEW
LI6680 Liver Cancer ADC? HCC? Right lobe of liver: cholangiocarcinoma with necrosis, grade II-III, cancer embolus present in vessel. CLICK TO VIEW
LI6683 Liver Cancer HCC Left lobe of liver: hepatocellular carcinoma, grade III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G2S4. CLICK TO VIEW
LI6686 Liver Cancer HCC Caudate lobe of liver: hepatocellular carcinoma, grade II-III, cancer embolus present in vessel. Peripheral hepatic tissues showed hodular cirrhosis G1S4. CLICK TO VIEW
LI6687 Liver Cancer NA Right lobe of liver: hepatocellular carcinoma with necrosis, grade III. Peripheral hepatic tissues showed hodular cirrhosis G2S2. CLICK TO VIEW
LI6688 Liver Cancer HCC Left lobe of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues did not form hodular cirrhosis G1S2. CLICK TO VIEW
LI6691 Liver Cancer HCC Right lobel of liver: mixed carcinoma of liver, mdoerately differentiated hepatocellular carcinoma mixed moderately differentiated cholangiocellular carcinoma. Peripheral hepatic tissues showed nodular cirrhosis G1S1 CLICK TO VIEW
LI6692 Liver Cancer NA Right posterior lobe of liver: poorly differentiated hepatocellular carcinoma with neuroendocrine differentiation. Peripheral hepatic tissues showed hodular cirrhosis G1S3-4. CLICK TO VIEW
LI6699 Liver Cancer HCC N/A CLICK TO VIEW
LI6700 Liver Cancer HCC Left lobel of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues showed nodular cirrhosis G2S4. CLICK TO VIEW
LI6708 Liver Cancer HCC Right lobel of liver: hepatocellular carcinoma, grade III. Peripheral hepatic tissues showed nodular cirrhosis G2S2. CLICK TO VIEW
LI6716 Liver Cancer HCC NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. CLICK TO VIEW
LI6717 Liver Cancer HCC NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. CLICK TO VIEW
LI6718 Liver Cancer HCC NA for clinical diagnosis info. Pathology QC: Hepatocellular carcinoma. CLICK TO VIEW
LI6722 Liver Cancer HCC Right lobe of liver: poorly differentiated adenocarcinoma, consider poorly differentiated cholangiocarcinoma on basis of IHC results. Peripheral hepatic tissues showed nodular cirrhosis (G2S4). CLICK TO VIEW
LI6723 Liver Cancer HCC Section IV of liver: hard to distinguish between poorly differentiated hepatocellular carcinoma and cholangiocarcinoma, considre as poorly differentiated hepatocellular carcinoma CLICK TO VIEW
LI9323 Liver Cancer NA NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login